FLI (2006) [81] |
=1/[1+exp (−Y)]×100, Y=0.953×loge (TG, mg/dL)+0.139×BMI+0.718×loge (GGT, U/L)+0.053×WC−15.745 |
≥60, <30 |
NAFLD by US (Italy) |
Yes (validated in Korean) |
SteatoTest (2005) [82] |
α2-Macroglobulin, haptoglobin, apolipoprotein A1, total bilirubin, GGT, FPG, TG, cholesterol, ALT, age, sex, BMI |
NA |
NAFLD by biopsy (France) |
Yes |
NAFLD liver fat score (2009) [83] |
=−2.89+1.18×MetS+0.45×diabetes (yes=2/no=0)+0.15×(fSinsulin, μU/L)+0.04×AST−0.94×AST/ALT |
>−0.64 |
NAFLD by MRS (Finland) |
Yes (validated in Korean) |
HIS (2010) [84] |
=8×ALT/AST+BMI (+2, if diabetes; +2, if female) |
≥36, <30 |
NAFLD by US (Korean) |
Yes (validated in Korean) |
CNS (2014) [80] |
=1/[1+exp (−Y)]×100 |
≥40 |
NAFLD by US (Korean) |
Yes (validated in Korean) |
Y (male)=0.016×age+0.182×BMI+0.089×WC+0.391×alcohol+0.124×exercise (yes=0/no=1)+0.018×FPG (mg/dL)+0.773×loge (TG, mg/dL)−0.014×HDL-C (mg/dL)+0.145×uric acid (mg/dL)−0.674×loge (AST)+1.632×loge (ALT)−21.695 |
Y (female)=0.320×BMI+0.044×WC+0.533×diabetes+0.016×FPG+0.951×loge (TG)−0.015×HDL-C+0.199×uric acid−0.645×loge (AST)+1.302×loge (ALT)+0.255×menopause−19.741 |
SNS (2014) [80] |
=Points, Age ≥35=1 |
≥8 |
NAFLD by US (Korean) |
Yes (validated in Korean) |
WC (male)=80–89/90–99/≥100=2/3/4 |
WC (female)=75–84/85–94/≥95=1/2/3 |
BMI (male)=23–24/25–26/≥27=1/2/3 |
BMI (female)=23–24/25–26/≥27=2/3/4 |
Diabetes=2 |
Dyslipidemia=2 |
No regular exercise=1 |
Alcohol=1 for male |
Menopause=1 for female |
ZJU index (2015) [85] |
=BMI+FPG (mmol/L)+TG (mmol/L)+3×ALT/AST (+2, if female) |
> 38, <32 |
NAFLD by US (China) |
Yes |
FSI (2016) [86] |
=−7.981+0.011×age (years)−0.146×sex (female=1, male=0)+0.173×BMI+0.007×TG (mg/dL)+0.593×hypertension+0.789×diabetes+1.1×ALT/AST ratio ≥1.33 (yes=1, no=0) |
≥23 |
NAFLD by CT (USA) |
Yes |
Chinese NAFLD score (2016) [87] |
=−4.632+0.303×MetS+0.157×T2DM (yes =2, no=0)+0.078×fSinsulin (μU/L)+0.168×BMI−0.879×AST/ALT |
>−0.79 |
NAFLD by US (China) |
Yes |